Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Recurrent Ovarian Clear Cell Carcinoma
NCT01824615Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2013
- Primary completion
- Jan 2016
- Countries
- 1
- Sponsor
- Cathay General Hospital
- Modality
- Small Molecules
- Drugs
- sunitinib
- Conditions
- ovarian clear cell carcinoma (OCCC)
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in ovarian clear cell carcinoma (OCCC), sponsored by Cathay General Hospital. Primary endpoint: Response Rate. Started Jan 2013; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Sunitinib
Sunitinib 37.5mg daily
03
Endpoints
Primary
Response Rate
Beyond the preview
Go deeper on NCT01824615.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824615.